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Abstract Excessive release of proinflammatory cytokines
mediates the toxic effect of superantigenic staphylococcal
exotoxins (SE). Baicalin, a flavone isolated from the Chinese
herb Scutellaria baicalensis Georgi and used in China to treat
infectious diseases, inhibited SE-stimulated T-cell proliferation
(by 98%) and production of interleukin 1L, interleukin 6, tumor
necrosis factor, interferon Q, monocyte chemotactic protein 1,
macrophage inflammatory protein (MIP)-1K, and MIP-1L
mRNA and protein by human peripheral blood mononuclear
cells. These data suggest that baicalin may be therapeutically
useful for mitigating the pathogenic effects of SE by inhibiting
the signaling pathways activated by superantigens. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Staphylococcal toxic shock syndrome toxin 1 (TSST-1) and
the distantly related enterotoxin A and B (SEA and SEB) are
potent activators of the immune system and cause a variety of
diseases in humans, ranging from food poisoning and toxic
shock to autoimmune diseases [1^5]. These toxins bind to
both the major histocompatibility complex class II molecules
on antigen-presenting cells and speci¢c VL regions of the T-
cell antigen receptors [6^9]. These toxins are called superanti-
gens because of their ability to polyclonally activate large
populations of T-cells [6]. Their interactions with cells of the
immune system result in a massive production of proin£am-
matory cytokines and chemokines [10^14]. The cytokines, tu-
mor necrosis factor (TNFK), interleukin 1 (IL-1), IL-6 and
interferon Q (IFNQ), are pivotal mediators in superantigen-in-
duced toxic shock [10,14]. Both TNFK and IL-1 have potent
immunostimulating activities and act synergistically with
IFNQ to enhance immune reactions and promote tissue injury
[15]. Consequently these cytokines are pathogenic at high con-
centrations in vivo and are responsible for fever and toxic
shock induced by SE [4,5,13,16].
Baicalin (BA, 7-glucuronic acid, 5,6-dihydroxy£avone) is a
£avone isolated from the Chinese medicinal herb Scutellaria
baicalensis Georgi and has been used to treat various infec-
tious and allergic diseases in China [17]. Its in vitro e¡ects
include the inhibition of reverse transcriptase activity in
HIV-1-infected cells [18,19] and interference with the interac-
tion of HIV-1 envelope proteins with chemokine receptors
[20]. Recently, BA was shown to bind selectively to several
chemokines (stromal cell-derived factor 1K, IL-8, macrophage
in£ammatory protein (MIP)-1L, monocyte chemotactic pro-
tein (MCP)-2, and lymphotactin) and interfere with the ability
of these chemokines to bind to chemokine receptors [21]. It
also blocked the proliferative e¡ect of platelet-derived growth
factor on vascular smooth muscle cells [22]. In vivo, BA sup-
pressed carrageenin-induced paw edema in rats [23,24] and
reduced chemokine-induced neutrophil in¢ltration in vivo
[21]. This study was undertaken to determine the e¡ect of
BA on staphylococcal superantigen-induced T-cell activation
and cytokine production from human peripheral blood mono-
nuclear cells (PBMC).
2. Materials and methods
2.1. Materials
Puri¢ed SEB and TSST-1 were obtained from Toxin Technology
(Sarasota, FL, USA). The endotoxin content of these preparations
was 6 1 ng endotoxin/mg protein, as determined by the Limulus
amoebocyte lysate assay (BioWhittaker, Walkersville, MD, USA).
Human (h) recombinant (r) TNFK, antibodies against hTNFK, per-
oxidase-conjugated anti-rabbit IgG, and peroxidase-conjugated anti-
goat IgG were obtained from Boehringer-Mannheim (Indianapolis,
IN, USA). Recombinant MCP-1, MIP-1K, MIP-1L ; antibodies
against hIL-1L, hIL-6, hMIP-1K, and MIP-1L were purchased from
RpD Systems (Minneapolis, MN, USA). Human caspase 3 and cas-
pase 8 assay kits were also obtained from RpD Systems. Human rIL-
1L was kindly provided by Dr. J. Oppenheim (National Cancer In-
stitute, Frederick, MD, USA). Human rIFNQ and rIL-6 were obtained
from Collaborative Research (Boston, MA, USA). Antibodies against
hIFNQ and MCP-1 were obtained from Pharmingen (San Diego, CA,
USA). BA was isolated and prepared as described previously [19]. All
other reagents were from Sigma (St. Louis, MO, USA).
2.2. Cell culture
Human PBMC were isolated by Ficoll-Hypaque density gradient
centrifugation of heparinized blood from normal human donors.
PBMC (106 cells/ml) were cultured at 37‡C in 24-well plates contain-
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ing RPMI 1640 medium and 10% heat-inactivated fetal bovine serum.
Cells were incubated with either SEB (150 ng/ml) or TSST-1 (150 ng/
ml) and the supernatants were harvested and analyzed for IL-1L,
TNFK, IL-6, IFNQ, MCP-1, MIP-1K, and MIP-1L. Cytokines and
chemokines were measured by an enzyme-linked immunosorbent as-
say (ELISA) with cytokine- or chemokine-speci¢c antibodies accord-
ing to the manufacturer’s instructions [11,25]. Human recombinant
cytokines and chemokines (20^1000 pg/ml) were used as standards
for calibration on each plate. The detection limit of each assay was
20 pg/ml. The cytokine and chemokine data were expressed as the
mean reading þ S.D. of duplicate samples. BA, when present, was
added simultaneously with SE. T-cell proliferation was assayed with
PBMC (105 cells/well), plated in triplicate with SEB or TSST-1 (150
ng/ml), with or without BA, for 48 h at 37‡C in 96-well microtiter
plates. Cells were pulsed with 1 WCi/well of [3H]thymidine (New Eng-
land Nuclear, Boston, MA, USA) during the last 5 h of culture as
described previously [25]. Cells were harvested onto glass ¢ber ¢lters,
and incorporated [3H]thymidine was measured by liquid scintillation.
2.3. RNase protection assay
Total RNA was isolated 4 h after SE treatment from cells by using
a guanidinium isothiocyanate/chloroform-based technique (Trizol,
Gibco, Grand Island, NY, USA) as per the manufacturer’s instruc-
tions. The RNase protection assay was performed as follows: total
cellular RNA (5^10 Wg) was hybridized with a [33P]UTP-labeled RNA
probe (mck-1, mck-2b, mck-3b, mck-5 utilizing the Pharmingen Ri-
boQuant In Vitro Transcription kit, 1U106 cpm/RNA sample) using
the Pharmingen hybridization bu¡er according to the manufacturer’s
directions (Pharmingen). After hybridization, the samples were treated
with RNase A and T1 according to the procedure provided by Phar-
mingen, the RNase was inactivated and the protected RNA precipi-
tated with a master cocktail containing 200 Wl Ambion (Austin, TX,
USA) RNase inactivation reagent, 50 Wl ethanol, 5 Wg yeast tRNA
and 1 Wl Ambion GycoBlue co-precipitate per RNA sample. The
samples were mixed well, incubated at 370‡C for 30 min and centri-
fuged at 14 000 rpm for 15 min at room temperature. The pellets were
resuspended in 3 Wl of Pharmingen sample bu¡er and subjected to
polyacrylamide gel electrophoresis as recommended by the manufac-
turer (Pharmingen).
2.4. Statistical analysis
All data were analyzed for signi¢cant di¡erences by the Student’s t-
test with Stata (Stata Corp., College Station, TX, USA). Di¡erences
between BA-treated and untreated control groups were considered
signi¢cant if P was 6 0.05.
3. Results and discussion
Based on the reports that BA blocked paw edema and
reduced neutrophils in¢ltration in vivo [21,23,24], we tested
the hypothesis that this natural £avonoid might have direct
e¡ects on the expression of proin£ammatory cytokines. As
shown in Fig. 1, BA, in a dose-dependent manner, blocked
the production of cytokines IL-1L, IL-6, TNFK, and IFNQ ;
and chemokines MCP-1, MIP-1K and MIP-1L from PBMC
Fig. 1. Dose^response inhibition of (A) IL-1L and IL-6, (B) TNFK
and IFNQ, and (C) MCP-1, MIP-1K, MIP-1L production by PBMC
stimulated with 150 ng/ml of SEB in the presence of various con-
centrations of BA. Values represent the mean þ S.D. of duplicate
samples from two experiments. Inhibition of all concentrations of
BA, with the exception of 1 Wg/ml, was statistically signi¢cant by
comparisons to control SEB-stimulated cells (P6 0.05).
Fig. 2. Inhibition of (A) IL-1L, TNFK, IL-6, and IFNQ and (B)
MCP-1, MIP-1K, and MIP-1L production by PBMC stimulated
with SEB (150 ng/ml), or TSST-1 (150 ng/ml) in the presence of 100
Wg/ml BA. Values represent the mean þ S.E.M. of PBMC cultures
from six blood donors. Results are statistically signi¢cant (P6 0.02)
between SE and SE plus BA samples.
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incubated with SEB. We observed near complete inhibition of
these cytokines and chemokines at 100 Wg/ml of BA. Similar
dose^response inhibition by BA was observed at lower con-
centrations of SEB (1 and 10 ng/ml). With 10 ng/ml of SEB,
TNFK and MIP-1K were blocked 45% and 35%, respectively,
by 10 Wg/ml BA. More complete inhibition of these mediators
was achieved at 100 Wg/ml of BA. BA was not cytotoxic to
PBMC at this concentration as measured by the exclusion of
trypan blue and the lack of lactate dehydrogenase release
from treated cells. Additionally, intracellular caspase 3 and
caspase 8 were absent from BA-treated PBMC.
The e¡ect of BA on cytokine and chemokine production by
TSST-1 was compared with that of SEB-stimulated cells from
six blood donors (Fig. 2). Production of IL-1L, IL-6, TNFK
and IFNQ by TSST-1-stimulated cells was inhibited 90%, 79%,
87% and 90%, respectively, by 100 Wg/ml BA. BA also de-
creased the levels of MCP-1, MIP-1K and MIP-1L 90%,
88% and 82%, respectively, in TSST-1-stimulated PBMC. In-
hibition of cytokines and chemokines in SEB-stimulated cells
was similar to that of TSST-1-stimulated cells.
Next we sought to determine if the inhibition of cytokine
and chemokine expression by BA was observed at the mRNA
level. Total RNA was extracted 4 h after treatment of the
PBMC with superantigen in the presence or absence of BA
or with BA alone. Gene expression was measured with a
Multiprobe RNase protection assay. In this assay, L32
rRNA and GAPDH RNA are used as internal standards
for RNA quantitation. As seen in Fig. 3, BA blocked SEB-
induced increase in the RNA for MIP-1K, MIP-1L, lympho-
tactin, IP-10, MCP-1, IFNQ, TNFK and L, lymphotoxin L and
IL-1K and L. Interestingly, IL-8 RNA expression was not
inhibited, indicating there was some selectivity in the e¡ects
of BA on SEB-induced gene expression. Thus, SEB-induced
IL-8 protein as measured by ELISA was inhibited by BA by
only 37% (data not shown). Also, while BA alone did not
alter cytokine/chemokine gene expression (Fig. 3, lane 4), lev-
els of cytokine/chemokine RNA present in the unstimulated
PBMC were also not a¡ected by BA, indicating that BA di-
rectly blocked the superantigen signaling pathway that leads
to new RNA synthesis.
As the ability of superantigens to induce T-cell proliferation
is well known, the e¡ect of BA on SE-induced T-cell prolif-
eration was analyzed. Fig. 4 shows that BA dose-dependently
inhibited SEB- and TSST-1-stimulated T-cell proliferation,
Fig. 3. Cytokine and chemokine mRNA analysis. Total RNA was extracted from human PBMC treated for 4 h with SEB in the presence or
absence of BA. Multiprobe RNase protection analysis was performed as described in Section 2 using 5 Wg of total RNA per lane. Lanes 1, 2,
3, and 4 represent cells in medium alone, SEB-stimulated cells, SEB-stimulated cells plus BA, and cells with BA, respectively. Data in each
probe set represent experiments repeated at least three times.
FEBS 24999 22-6-01
T. Krakauer et al./FEBS Letters 500 (2001) 52^5554
achieving 99% inhibition at 100 Wg/ml of BA. Suppression of
T-cell proliferation by BA was not due to the cytotoxic e¡ect
of BA as cells were 90% viable by the trypan blue exclusion
test.
This study demonstrated that BA e¡ectively inhibited
superantigen-mediated production of cytokines and chemo-
kines by human PBMC in vitro. Previous reports indicate
that monocytes are the cell source of the cytokine IL-1L
and the chemokines, MCP-1, MIP-1K and L [11,26]. In addi-
tion, T-cell proliferation induced by staphylococcal superanti-
gens was also completely suppressed. Therefore, BA most
likely exerts its e¡ects on both monocytes and T-cells.
Down-regulation of proin£ammatory cytokines and chemo-
kines by BA in SEB- and TSST-1-stimulated PBMC suggests
that BA may a¡ect the pathophysiology of toxic shock. In
view of recent clinical studies showing the failure of TNF
receptor:Fc protein [27] or IL-1 receptor antagonist [28] in
the treatment of septic shock, novel small molecular weight
inhibitors capable of suppressing multiple proin£ammatory
cytokines may prove more useful in the management of shock.
Recently, an emerging neonatal exanthematous disease was
found to be induced by TSST-1 produced by methicillin-resis-
tant Staphylococcus aureus [29,30]. BA may also be useful in
the treatment of this neonatal infection because hyperactiva-
tion of T-cells plays a prominent role in this disease. In con-
clusion, this study clearly indicates that BA down-regulates
expression of proin£ammatory cytokines and chemokines,
thus suggesting its potential utility for treating superantigen-
induced toxic shock.
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Fig. 4. Inhibition of T-cell proliferation in PBMC stimulated with
150 ng/ml of SEB or TSST-1 by varying concentrations of BA. Val-
ues are the mean counts þ S.E.M. of triplicate cultures and represent
¢ve experiments. Results are statistically signi¢cant (P6 0.02) be-
tween SE and SE plus BA samples at both 10 and 100 Wg/ml of
BA.
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